A randomised study of Mitomycin, Vinblastine and Platinum (cisplatin) (MVP) three versus six cycles in advanced Non-Small Cell Lung Cancer (NSCLC)
Not Applicable
Completed
- Conditions
- ung (non-small cell) cancerCancerLung (non-small cell) cancer
- Registration Number
- ISRCTN57675565
- Lead Sponsor
- Cancer Research UK (CRUK) (UK)
- Brief Summary
2001 results in: https://www.ncbi.nlm.nih.gov/pubmed/11230476 (added 16/04/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 308
Inclusion Criteria
1. Histological evidence of NSCLC
2. Stage IIIb or IV disease not eligible for surgery or radical radiotherapy
3. Performance status zero, one or two
4. Ability to give signed, informed consent
5. 51Cr Ethylene Diamine Tetraacetic Acid (EDTA) more than 60 ml/min, creatinine clearance more than 60 ml/min, Haemoglobin (Hb) more than 10 g/dl, White Cell Count (WCC) more than 3 x 10^9/l, platelets 100 x 10^12/l, Liver Function Tests (LFTs) not more than two times normal unless due to metastatic disease
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration